Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience.

@article{Song2014GemcitabineAD,
  title={Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience.},
  author={Bong Sup Song and Juhee Seo and Dong Ho Kim and Jung Sub Lim and Ji young Yoo and Jun Ah Lee},
  journal={Pediatric blood & cancer},
  year={2014},
  volume={61 8},
  pages={
          1376-81
        }
}
BACKGROUND We evaluated the efficacy of gemcitabine and docetaxel chemotherapy (GEM + DOC) in children and adolescents with recurrent or refractory osteosarcoma. METHODS Data of 28 patients (20 male, 8 female) who received gemcitabine (675 or 900 mg/m(2) on days 1 and 8) and docetaxel (100 mg/m(2) on day 8) at Korea Cancer Center Hospital were retrospectively reviewed. RESULTS Patients (ages 5.0-19.7 years) received a total of 96 courses of chemotherapy (median 3 courses; range, 1-8 courses… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma. Oncolosist 2012;17:321

  • E Fox, S Patel, JK Wathen
  • Pediatr Blood Cancer DOI 10.1002/pbc
  • 2012